Olympus 7733.T
Olympus Corporation is a Japanese medical technology company that designs and manufactures endoscopes, minimally invasive diagnostic and treatment solutions, as well as imaging equipment for the healthcare sector. Olympus shows exceptional growth (earnings +122.6%) and a solid balance sheet (ND/EBITDA 0.92), but its valuation (P/E 33.05) and weak free cash flow conversion (7.91%) limit appeal. The endoluminal robotics deal could be a key catalyst.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Olympus Corporation is a Japanese medical technology company that designs and manufactures endoscopes, minimally invasive diagnostic and treatment solutions, as well as imaging equipment for the healthcare sector. Olympus shows exceptional growth (earnings +122.6%) and a solid balance sheet (ND/EBITDA 0.92), but its valuation (P/E 33.05) and weak free cash flow conversion (7.91%) limit appeal. The endoluminal robotics deal could be a key catalyst.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.7 |
| Quality / Moat | 5.2 |
| Valuation | 4.1 |
| Growth | 8.9 |
| Dividend | 6.3 |
| Momentum | 7.3 |
| Risk & Context | 9.0 |
OVERALL SCORE: 6.5/10
Context and risks
Moderate regulatory risk in Japan and PolyLoop product recall that could attract additional scrutiny. No material exposure to rates, oil, or geopolitics.
News considered in the analysis
- Olympus’ Endoluminal Robotics Distribution Deal Could Be A Game Changer For Olympus (TSE:7733) — Acuerdo de distribución en robótica endoluminal que podría ampliar significativamente su cartera de productos y mercado direccionable, aunque aún no se han materializado ingresos.
- Olympus launches second VC fund with $150m commitment — Lanzamiento de un segundo fondo de capital riesgo de 150 millones de dólares para invertir en innovación médica; refuerza su estrategia de crecimiento a largo plazo.
- Should Olympus’ PolyLoop Recall and VIABIL Deal Reshape the Medtech Story for Olympus (TSE:7733) Investors? — Retirada del producto PolyLoop y el acuerdo con VIABIL generan incertidumbre sobre la calidad y la estrategia, pero el impacto financiero parece limitado.
Verdict: Hold; growth is strong, but valuation and cash generation warrant caution.
Main risk: Weak free cash flow conversion (7.91%) and the PolyLoop product recall could indicate operational or quality issues affecting confidence.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →